mhurhangee/ep-ind-claims huggingface dataset:
A method for recovering a composition enriched in 3-hydroxypropionic acid from a fermentation broth comprising 3-hydroxypropionic acid and/or salts thereof, the method comprising the steps of: (a) providing the fermentation broth having a pH of from 2 to 8 comprising: 3-hydroxypropionic acid and/or salts thereof, and sulfate ions and phosphate ions; (b) increasing the concentration of 3-hydroxypropionic acid and/or salts thereof in the fermentation broth of step (a) to from 100 to 500 grams of 3-hydroxypropionic acid equivalents per liter of broth by evaporating at least a portion of the liquid present in the fermentation broth; (c) acidifying the fermentation broth from step (b) to lower the pH to from 1 to 3 to form an aqueous solution comprising 3-hydroxypropionic acid; (d) reducing the total sulfate ion and phosphate ion concentration of the aqueous solution to produce a reduced ion aqueous solution comprising 3-hydroxypropionic acid; (e) distilling the reduced ion aqueous solution at a pH of from 1 to 3 by applying vacuum and heat to the reduced ion aqueous solution to form an aqueous distillation product comprising 3-hydroxypropionic acid; and (f) recovering the aqueous distillation product comprising 3-hydroxypropionic acid at a concentration of at least thirty percent by weight of the aqueous distillation product and wherein the aqueous distillation product comprises less than five parts by weight acrylic acid per one hundred parts by weight 3-hydroxypropionic acid present. (a) providing the fermentation broth having a pH of from 2 to 8 comprising: 3-hydroxypropionic acid and/or salts thereof, and sulfate ions and phosphate ions; 3-hydroxypropionic acid and/or salts thereof, and sulfate ions and phosphate ions; (b) increasing the concentration of 3-hydroxypropionic acid and/or salts thereof in the fermentation broth of step (a) to from 100 to 500 grams of 3-hydroxypropionic acid equivalents per liter of broth by evaporating at least a portion of the liquid present in the fermentation broth; (c) acidifying the fermentation broth from step (b) to lower the pH to from 1 to 3 to form an aqueous solution comprising 3-hydroxypropionic acid; (d) reducing the total sulfate ion and phosphate ion concentration of the aqueous solution to produce a reduced ion aqueous solution comprising 3-hydroxypropionic acid; (e) distilling the reduced ion aqueous solution at a pH of from 1 to 3 by applying vacuum and heat to the reduced ion aqueous solution to form an aqueous distillation product comprising 3-hydroxypropionic acid; and (f) recovering the aqueous distillation product comprising 3-hydroxypropionic acid at a concentration of at least thirty percent by weight of the aqueous distillation product and wherein the aqueous distillation product comprises less than five parts by weight acrylic acid per one hundred parts by weight 3-hydroxypropionic acid present.
A cable for a hearing device, comprising a plurality of conductors, characterized in that the plurality of conductors comprises conductors arranged in twisted pairs (TP1 to TP4) wound around a plastically deformable core wire, wherein the core wire is a forming wire.
A computer-implemented method for compressive sensing, comprising determining optimal sampling grid during seismic data reconstruction, the method comprising: a) constructing an optimization model, via a computing processor, given by min u ∥ Su ∥ 1 s.t. ∥ Ru - b ∥ 2 ≤ σ wherein S is a discrete transform matrix, b is seismic data on an observed grid, u is seismic data on a reconstruction grid, σ is a representative of the noise level in the observed data and matrix R is a sampling operator; b) defining mutual coherence as μ ≤ C S m log n 6, wherein C is a constant, S is a cardinality of Su, m is proportional to number of seismic traces on the observed grid, and n is proportional to number of seismic traces on the reconstruction grid; c) deriving a mutual coherence proxy, wherein the mutual coherence proxy is a proxy for mutual coherence when S is over-complete and wherein the mutual coherence proxy is exactly the mutual coherence when S is a Fourier transform; and d) determining a sample grid r ∗ = arg min r μ ( r); wherein the sample grid is determined via randomized greedy algorithm method or via stochastic global optimization method. a) constructing an optimization model, via a computing processor, given by min u ∥ Su ∥ 1 s.t. ∥ Ru - b ∥ 2 ≤ σ wherein S is a discrete transform matrix, b is seismic data on an observed grid, u is seismic data on a reconstruction grid, σ is a representative of the noise level in the observed data and matrix R is a sampling operator; b) defining mutual coherence as μ ≤ C S m log n 6, wherein C is a constant, S is a cardinality of Su, m is proportional to number of seismic traces on the observed grid, and n is proportional to number of seismic traces on the reconstruction grid; c) deriving a mutual coherence proxy, wherein the mutual coherence proxy is a proxy for mutual coherence when S is over-complete and wherein the mutual coherence proxy is exactly the mutual coherence when S is a Fourier transform; and d) determining a sample grid r ∗ = arg min r μ ( r);
Process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)-benzamidine of formula wherein R 1 denotes a methyl group, R 2 denotes an R 21 NR 22 group, wherein R 21 denotes an ethyl group which is substituted by an ethoxycarbonyl group, and R 22 denotes a pyridin-2-yl group, and R 3 denotes a hexyloxycarbonyl group, wherein in step (a) a phenyldiamine of formula wherein R 1 and R 2 have the meanings given for formula, is reacted with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid; the resulting product of formula wherein R 1 and R 2 have the meanings given for formula, is hydrogenated in step (b), and (c) the compound of formula thus obtained, wherein R 3 denotes hydrogen, is optionally reacted with a compound of formula R 3 -X wherein R 3 has the meaning given for formula, and X denotes a suitable leaving group. R 1 denotes a methyl group, R 2 denotes an R 21 NR 22 group, wherein R 21 denotes an ethyl group which is substituted by an ethoxycarbonyl group, and R 22 denotes a pyridin-2-yl group, and R 21 denotes an ethyl group which is substituted by an ethoxycarbonyl group, and R 22 denotes a pyridin-2-yl group, and R 3 denotes a hexyloxycarbonyl group, wherein in step (a) a phenyldiamine of formula wherein R 1 and R 2 have the meanings given for formula, is reacted with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)-phenylamino]-acetic acid; the resulting product of formula (c) the compound of formula thus obtained, wherein R 3 denotes hydrogen, is optionally reacted with a compound of formula R 3 -X
A polymeric matrix for the controlled-release delivery of a genetically-engineered baculovirus in a vertebrate individual, said polymeric matrix comprising biocompatible biodegradable polymers, and having at least partially embedded therein a plurality of genetically-engineered baculoviruses, wherein each baculovirus lacks the ability of replicating in the cells of the vertebrate individual, wherein the biodegradable polymers comprise polyesters and wherein cationic polymers form a coat covering at least a portion of the surface of the plurality of baculoviruses.
An antigen-concentration measurement/detection kit comprising an antibody light-chain variable region polypeptide and an antibody heavy-chain variable region polypeptide, either one of which is labeled with a fluorescent dye that is quenched in the state where it is labeled to the antibody heavy-chain variable region polypeptide or the antibody light-chain variable region polypeptide, wherein the quench is eliminated when the antibody heavy-chain variable region polypeptide and the antibody light-chain variable region polypeptide form a complex via an antigen to increase a fluorescence intensity, and wherein the kit enables a measurement of antigen concentration or visualization of the antigen with reference to a positive correlation between the concentration of the antigen in a liquid phase and the fluorescence intensity of the fluorescent dye.
Vacuum nozzle, in particular for a portable hard surface vacuum device comprising a vacuum apparatus, said vacuum nozzle having a suction opening which a suction channel adjoins, the end of the suction channel that faces away from the suction opening being connectable to the vacuum apparatus, wherein a joint is arranged or formed between the suction opening and the suction channel end for moving the suction opening relative to the suction channel end and wherein a blocking device is provided for blocking the joint in force-locking and/or positive-locking manner in at least one blocking position, characterised in that the joint defines at least one pivot axis, in that the joint comprises first and second joint elements (50, 54) which engage and cooperate with one another, and which, in an adjusting position, are pivotable relative to one another about the at least one pivot axis, in that the blocking device comprises a locking mechanism with first and second locking elements (106, 108), which in at least one locking position are in engagement and, in the adjusting position, are out of engagement, in that the first and second locking elements (106, 108) are associated on the one hand with the first joint element and on the other hand with the second joint element and in that in the at least one locking position, the first and second joint elements (50, 54) are held immovably against one another, in that the locking mechanism comprises at least one biasing element which, in a basic position of the locking mechanism, holds the first and second locking elements (106, 108) in the locking position, and in that the biasing element is arranged or formed on the first or second joint element (50, 54) or on the first or second locking element (106, 108).
An effector moiety capable of inducing an intracellular effect when present inside a mammalian cell, the effector moiety conjugated with at least one saponin, wherein the at least one saponin is a triterpenoid saponin and/or a bisdesmosidic triterpene saponin belonging to the type of a 12,13-dehydrooleanane with an aldehyde function in position C-23, wherein the at least one saponin is covalently bound involving a hydrazone bond to the effector moiety via at least one linker, or is covalently bound directly to said effector moiety, wherein the effector moiety comprises or consists of at least one oligonucleotide, a nucleic acid, a xeno nucleic acid.
Use of an aerosol precursor composition mixing system with an aerosol delivery device, said aerosol precursor composition mixing system comprising: a source container configured to contain an aerosol precursor composition and pressurized propellant in a source container body, and defining a source container outlet, a source container outlet valve being coupled to the source container outlet; and a mixing container defining a mixing container inlet and a mixing container outlet, a mixing container inlet valve being coupled to the mixing container inlet and a mixing container outlet valve being coupled to the mixing container outlet, the source container outlet valve and the mixing container inlet valve being configured to engage one another and open during engagement to allow transfer of the aerosol precursor composition from the source container to the mixing container, the pressurized propellant being configured to expel the aerosol precursor composition from the source container body when the source container outlet valve is open, the mixing container outlet valve being configured to open during engagement with the aerosol delivery device, the aerosol delivery device comprising a reservoir, an electrical power source and a control component, and dispense the aerosol precursor composition from the mixing container to the reservoir. a source container configured to contain an aerosol precursor composition and pressurized propellant in a source container body, and defining a source container outlet, a source container outlet valve being coupled to the source container outlet; and a mixing container defining a mixing container inlet and a mixing container outlet, a mixing container inlet valve being coupled to the mixing container inlet and a mixing container outlet valve being coupled to the mixing container outlet, the source container outlet valve and the mixing container inlet valve being configured to engage one another and open during engagement to allow transfer of the aerosol precursor composition from the source container to the mixing container, the pressurized propellant being configured to expel the aerosol precursor composition from the source container body when the source container outlet valve is open, the mixing container outlet valve being configured to open during engagement with the aerosol delivery device, the aerosol delivery device comprising a reservoir, an electrical power source and a control component, and dispense the aerosol precursor composition from the mixing container to the reservoir.
A dilation device comprising: a tubular support; an inflatable dilation portion that is attached to the tubular support; and an inflation lumen (40; 42; 46; 48); the device characterised by an inflatable stiffening portion. a tubular support; an inflatable dilation portion that is attached to the tubular support; and an inflation lumen (40; 42; 46; 48); the device characterised by an inflatable stiffening portion.
Device for registering and destroying individual tumor cells, tumor cell clusters, and micro metastases in the circulatory system, which are enriched with a photo-sensitive substance, the device comprising - a radiation source (7, 11) adapted to intravascularly or extra vascularly excite the photo-sensitive substance - a fiber optic cable (1, 12, 13) for intravascularly or extra vascularly conducting a fluorescence and/or phosphorescence- and/or luminescence radiation of the excited tumor cells and/or tumor cell clusters and/or micro metastases - a high sensitivity fluorescence spectrometer, connected to said fiber optic cable (1, 12, 13), for registering the radiation emitted - a computer, connected to said spectrometer, for recording the received peaks of the radiation emitted as a function of time, the device comprising - a further radiation source acting intravascularly or extra vascularly, arranged, in the direction of blood flow, downstream from said detector (1, 12, 13) and connected to said computer, adapted to put out a switch-on signal to said second radiation source upon registering a radiation peak, this further radiation source being adapted to destroying tumor cells and/or tumor cell clusters and/or micro metastases by means of photo-dynamic therapy by emission of light in the wavelength of the radiation peak. - a radiation source (7, 11) adapted to intravascularly or extra vascularly excite the photo-sensitive substance - a fiber optic cable (1, 12, 13) for intravascularly or extra vascularly conducting a fluorescence and/or phosphorescence- and/or luminescence radiation of the excited tumor cells and/or tumor cell clusters and/or micro metastases - a high sensitivity fluorescence spectrometer, connected to said fiber optic cable (1, 12, 13), for registering the radiation emitted - a computer, connected to said spectrometer, for recording the received peaks of the radiation emitted as a function of time, the device comprising - a further radiation source acting intravascularly or extra vascularly, arranged, in the direction of blood flow, downstream from said detector (1, 12, 13) and connected to said computer, adapted to put out a switch-on signal to said second radiation source upon registering a radiation peak, this further radiation source being adapted to destroying tumor cells and/or tumor cell clusters and/or micro metastases by means of photo-dynamic therapy by emission of light in the wavelength of the radiation peak.
A pharmaceutical composition containing a mixture of 2 natural and/or modified GnRH variants, wherein one of the variants contains a carrier molecule bound to its carboxyl terminal end and the other variant contains the same or another carrier molecule bound to its amino terminal end, wherein the GnRH variants are selected from natural GnRH, retro-inverse GnRH, synthesized by D amino-acids, and mimetics thereof wherein said mimetics have the sequence of SEQ ID NO:1, and wherein the carrier molecule is a protein or a fragment or epitope thereof that increases the visibility of said GnRH variants for the immune system.
Extracorporeal blood pump for aspiration and displacement of blood, wherein the blood pump has one or two blood chambers and a mechanical drive unit, each of the blood chambers having a membrane, a blood inlet channel and a blood outlet channel, - wherein in the case of the blood pump with one blood chamber, the drive unit is adjacent to the blood chamber, wherein the drive unit has a gas inlet and a gas outlet as well as two pressure chambers, wherein each pressure chamber has an active surface, wherein a blood chamber is separated from a pressure chamber via a membrane, wherein the drive unit is actively connected to the position of the membrane, and wherein an area between the active surface and the membrane has a coupling rod which is designed to couple the movement of the active surface and the membrane to one another; - wherein in the case of the blood pump with two blood chambers, the drive unit is arranged between the blood chambers, the blood outlet channels of both blood chambers are connected to one another and an area between the membranes has a coupling rod which is designed to couple the movement of the two membranes to one another, whereby the drive unit has a gas inlet and a gas outlet as well as a pressure chamber, wherein the pressure chamber is separated from a blood chamber via a membrane, wherein the drive unit is actively connected to the position of the membrane. - wherein in the case of the blood pump with one blood chamber, the drive unit is adjacent to the blood chamber, wherein the drive unit has a gas inlet and a gas outlet as well as two pressure chambers, wherein each pressure chamber has an active surface, wherein a blood chamber is separated from a pressure chamber via a membrane, wherein the drive unit is actively connected to the position of the membrane, and wherein an area between the active surface and the membrane has a coupling rod which is designed to couple the movement of the active surface and the membrane to one another; - wherein in the case of the blood pump with two blood chambers, the drive unit is arranged between the blood chambers, the blood outlet channels of both blood chambers are connected to one another and an area between the membranes has a coupling rod which is designed to couple the movement of the two membranes to one another, whereby the drive unit has a gas inlet and a gas outlet as well as a pressure chamber, wherein the pressure chamber is separated from a blood chamber via a membrane, wherein the drive unit is actively connected to the position of the membrane.
A formwork assembly for moulding an upwardly extending building feature, the formwork assembly comprising at least two surface forming elements for forming at least one side of said building feature, wherein each surface forming element comprises a rectilinear frame secured to one side of a planar board member, and a border extending about a perimeter of the board member so as to form a continuous casting surface along with the board member, the border extending beyond at least one edge of the frame to form a flange, and further comprising at least one removable connecting element located between the two surface forming elements, wherein the or each connecting element comprises a cap for location between the flanges of adjacent surface forming elements, and characterized in that said connecting element further comprises a body shaped to fill the void behind the flanges and between the frames, such that adjacent edges of the surface forming elements abut against the connecting element so that the resulting formwork assembly forms a single, continuous casting surface, and in that in use, the or each connecting element is separately releasable from the formwork assembly to subsequently allow removal of the remaining surface forming elements once a concrete surface has been formed.
Device for coating containers, comprising a vacuum chamber, a plasma generator and a gas lance having an outlet opening in its end section and protruding into the container during normal operation and serving to introduce a material to be deposited on the inner wall of the container and as an antenna for electromagnetic field orientation in the vacuum chamber, wherein the internal diameter of the gas lance in the region of the outlet opening is enlarged relative to the internal diameter (d) in a main section of the gas lance, characterized in that the gas lance is widened in the shape of a trumpet or cone in the region of the outlet opening.
A thermoforming assembly for relief forming of plate of thermoplastic materials, said assembly comprising a lower mold part and an upper mold part, the two mold parts being movable in translation the one to the other along a substantially vertical direction between an opened position where said two mold parts (20, 34) are spaced apart the one to the other and a closed position where said two mold parts are engaged the one into the other, said assembly further comprising holding members to be able to hold a softened thermoplastic material plate, along a substantially horizontal middle plan Pm between said two mold parts; characterized in that said holding members comprise a plurality of rods movably mounted into said lower mold part, and in that said rods protrude from said lower mold part, when said two mold parts (20, 34) are in said opened position, to be able to hold said softened thermoplastic material plate along said substantially horizontal middle plan Pm.